Research conducted in the lab of Zymedyne Co-Founder and CSO Dr. Gerald Zamponi, has now been published in the prestigious Journal of experimental Medicine (JEM). The results of this work validate Zymedyne’s unique target – Cav3.2/USP5, as a potential therapeutic avenue for chronic pain treatment in humans.
Zymedyne published in prestigious Journal of experimental Medicine (JEM)